Common questions about DRAXXIN (FAQ)
Q: Is DRAXXIN approved for use in humans?
Official product labels and regulatory documents contain explicit warnings stating that DRAXXIN is for use in animals only and not for human use. The drug is a prescription veterinary medicine whose administration is strictly controlled by licensed veterinarians.
Q: What is the difference between DRAXXIN and DRAXXIN Plus?
DRAXXIN is a single-ingredient product containing only the antibiotic tulathromycin. DRAXXIN Plus is a different formulation that combines the antibiotic tulathromycin with ketoprofen, which is a nonsteroidal anti-inflammatory drug (NSAID).
Q: What are the main diseases DRAXXIN is used to treat in cattle and swine?
Official product information states that DRAXXIN is indicated for the treatment and control of Bovine Respiratory Disease (BRD) in cattle and Swine Respiratory Disease (SRD) in pigs. In cattle, it is also approved for treating specific infections such as Pinkeye and Foot Rot.
Q: Are there any diseases DRAXXIN is used to treat in sheep?
Yes, regulatory documents authorize the use of DRAXXIN in sheep for the treatment of infectious foot rot in its early stages. This specific use is restricted to certain types of susceptible bacteria.
Q: Does DRAXXIN have bacteriostatic or bactericidal action?
As a member of the macrolide class of antibiotics, tulathromycin is primarily considered bacteriostatic, which means it works by inhibiting the growth and multiplication of bacteria. However, official information notes that it may exhibit bactericidal (bacteria-killing) activity against certain specific types of pathogens.
Q: What is the meaning of the 'withdrawal period' for DRAXXIN, and what are the required times?
The withdrawal period is the mandatory waiting time that must pass after the last drug administration before an animal can be slaughtered for human consumption. This period is set by regulatory bodies to prevent drug residues in the meat. Official labels state the required times vary, but typically fall within ranges such as 18 to 22 days for cattle and 5 to 13 days for swine, depending on the specific product formulation and region of use.
Q: Is the meat from animals treated with DRAXXIN safe for human consumption after the withdrawal period? / Are there risks of drug residues in food products after treatment?
Regulatory agencies mandate the withdrawal period specifically to ensure that the meat from treated animals is compliant with established safe limits for drug residues (MRLs). If the official withdrawal period is strictly followed, the meat is considered compliant and meets regulatory compliance standards for human consumption.
Q: What is the typical timeframe for seeing the drug's effect after use?
Official guidelines recommend that the animal's clinical response to the single treatment be evaluated within 48 hours after administration. This 48-hour timeline serves as the official benchmark for veterinarians to determine if the treatment has been satisfactory or if a change in antimicrobial therapy is necessary.
Q: How long does the antibiotic stay active in the treated animal's system?
Studies indicate that the unique chemical structure of the drug allows it to persist in the animal’s system. Official product information indicates it maintains a concentration intended for therapeutic effect for approximately 9 to 14 days after a single injection.
Q: What kind of local reactions are seen at the injection site in pigs?
Regulatory documents classify injection site reactions in pigs as very common adverse effects. These reactions can include swelling, edema, hemorrhage (bruising), and the formation of fibrosis (persistent fibrous tissue), which may last for approximately 30 days after injection.
Q: Are there different formulations or concentrations of DRAXXIN available?
Yes, the drug is manufactured in different formulations designed for various applications and animal sizes. It is typically available as a 100 mg/ mL concentration, but a lower concentration of 25 mg/ mL is also approved and available for use in smaller animals.
Q: What happens if a person has accidental skin contact, gets the drug in their eyes, or has accidental self-injection?
Official safety information directs that in case of eye contact, the eyes should be flushed with clean water. For skin contact, the area should be washed with soap and water. If accidental self-injection occurs, the label states the person must immediately seek medical advice.
Q: What are the known potential adverse effects if a person were to swallow the drug?
Safety data sheets document the requirement that a physician or poison control center be contacted if the product is swallowed. Potential effects from oral exposure are generally associated with gastrointestinal irritation, which may include vomiting and diarrhea.
Q: Why is it recommended to wear protective gear when handling DRAXXIN?
Official precautions are recommended to minimize the risk of human exposure. It is advised to wear protective gloves and wash hands after use, as the product is an eye irritant and carries a risk of causing sensitization (allergic reactions) upon contact with the skin.
Q: Is DRAXXIN considered an antimicrobial important for human medicine?
Yes. While DRAXXIN is only for veterinary use, its active ingredient, tulathromycin, belongs to the macrolide class of antimicrobials. This class is formally classified by global organizations like the World Health Organization (WHO) as highly important or critically important for use in human medicine.
Q: How long has DRAXXIN been approved by regulatory bodies like the FDA or EMA?
Regulatory documents indicate a long-standing approval. For example, the European Medicines Agency (EMA) first authorized the use of the medicine in the European Union in 2008, establishing its timeline of regulatory oversight.
